Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration
Launched by MERCK KGAA, DARMSTADT, GERMANY · Sep 3, 2010
Trial Information
Current as of May 18, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Have relapsing remitting multiple sclerosis and currently receiving Rebif treatment and using the Rebiject II injection device
- • Be under regular review by a MS nurse
- • Be aged 18 or above
- • Be willing and able to participate in the trial and to have provided written informed consent
- Exclusion Criteria:
- • Receiving disease modifying therapy other than Rebif
- • Receiving Rebif but not using the Rebiject II injection device
- • Do not self inject
- • Are unable or unwilling to provide informed consent
About Merck Kgaa, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading global science and technology company, specializing in healthcare, life sciences, and performance materials. With a rich history dating back to 1668, Merck KGaA is committed to advancing innovative solutions that improve the quality of life for patients and drive scientific discovery. The company invests significantly in research and development to bring cutting-edge therapies to market, focusing on areas such as oncology, immunology, and neurology. As a dedicated clinical trial sponsor, Merck KGaA collaborates with healthcare professionals and institutions worldwide to conduct rigorous trials that ensure the safety and efficacy of its products, ultimately aiming to enhance patient outcomes and foster global health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Dr Gillian L Shepherd, MD, MRCP
Study Director
Merck Serono Limited, UK
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials